01—Abstract
Summary
Summary of the 8-K filed January 30, 2026. Cited figures are marked; the original filing is the authoritative source.
On January 30, 2026, Illumina, Inc. (NASDAQ: ILMN) completed its acquisition of SomaLogic and related assets from Standard BioTools Inc. under a Stock Purchase Agreement dated June 22, 2025.
The Business acquired is Standard BioTools' aptamer-based and functional proteomics business, including KREX, Single SOMAmer, translational and diagnostic assays, and excludes its mass cytometry and microfluidics businesses. The company paid a purchase price of $350,000,000a in cash, subject to customary adjustments, and the release states the deal was funded with cash on hand. The agreement also provides for royalty streams tied to revenues from certain products and services, plus up to $75,000,000 in potential milestone payments to Standard BioTools.
The company's press release describes the transaction as expanding its multiomics portfolio and its presence in the proteomics market, and says Illumina will discuss the financial implications of the transaction on its earnings call scheduled for February 5, 2026. The filing includes standard forward-looking statement cautions, citing risks such as integration of the Business, customer uptake of new products, manufacturing and reliance on third-party suppliers. The Purchase Agreement's representations and warranties are qualified and are not intended as statements of fact for investors.
02—Key points
Key Highlights
- Illumina completed the acquisition of SomaLogic and other specified assets from Standard BioTools on January 30, 2026.
- Cash purchase price of $350,000,000, subject to customary adjustments, paid at closing and funded with cash on hand.
- Additional consideration includes royalty streams tied to revenues from certain products and services and up to $75,000,000 in potential milestone payments.
- Acquired business is Standard BioTools' aptamer-based and functional proteomics business, including KREX, Single SOMAmer, and translational and diagnostic assays.
- Standard BioTools' mass cytometry and microfluidics businesses were excluded from the transaction.
- Illumina states the acquisition expands its multiomics portfolio and proteomics market presence, building on a co-development relationship with SomaLogic since late 2021.
- Financial implications of the transaction are to be discussed on the earnings call scheduled for February 5, 2026.
03—Questions
Frequently Asked Questions
What did Illumina acquire and from whom?
Illumina acquired SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd from Standard BioTools Inc. This gives Illumina Standard BioTools' aptamer-based and functional proteomics business, including KREX, Single SOMAmer, and translational and diagnostic assays.
How much did Illumina pay for the transaction?
Illumina paid a purchase price of $350,000,000 in cash at closing, subject to customary adjustments. The press release states the deal was funded with cash on hand.
Are there additional payments beyond the closing price?
Yes. The Purchase Agreement provides for royalty streams tied to revenues from certain products and services, plus up to $75,000,000 in potential milestone payments to Standard BioTools.
What parts of Standard BioTools' business were not included?
The transaction excludes Standard BioTools' mass cytometry and microfluidics businesses.
When will investors get more detail on the financial impact?
According to the press release, Illumina will discuss the financial implications of the transaction on its upcoming earnings call scheduled for February 5, 2026.
04—Continue